ADMA Biologics, Inc.
- Jurisdiction
United States - ISIN
US0008991046 (ADMA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€27.14 ∞% undervalued - Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€404.45M - Gross margin
53.0% - EBIT
€132.75M - EBIT margin
32.8% - Net income
€178.21M - Net margin
44.1%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
|
|
|
|
| Grossman Adam S | President and CEO |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)